Dogwood Therapeutics DWTX Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's business segments — net income loss?
- Dogwood Therapeutics (DWTX) reported business segments — net income loss of -$4.99M in Q1 2026.
- How has Dogwood Therapeutics's business segments — net income loss changed year-over-year?
- Dogwood Therapeutics's business segments — net income loss increased by 53.6% year-over-year, from -$10.73M to -$4.99M.
- What is the long-term trend for Dogwood Therapeutics's business segments — net income loss?
- Over 2 years (2023 to 2025), Dogwood Therapeutics's business segments — net income loss has grown at a 223.7% compound annual growth rate (CAGR), from -$5.3M to -$55.51M.
- What does business segments — net income loss mean?
- This metric represents the total profit or loss for the business segment after accounting for all operating expenses, research and development costs, and non-operating items. It serves as the primary indicator of the company's overall financial performance and its ability to sustain operations while advancing its drug pipeline.